Abstract
1075 Background: nab-P is an albumin-bound formulation of paclitaxel approved in 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, based on an international phase 3 trial comparing nab-P with paclitaxel on an every 3 week (q3w) schedule. The objective of this study was to characterize safety and efficacy outcomes of nab-P in MBC in the United States using health insurance claims data. Methods: A retrospective claims analysis was conductedusing the Optum Research Database (United Health affiliate). The analysis included women aged ≥ 18 years diagnosed with MBC (≥ 2 claims of BC diagnosis separated by ≥ 30 days and ≥ 2 claims of metastatic spread) prior to nab-P initiation. Pts had ≥ 6 months of continuous enrollment in a US health insurance plan from January 2005 through September 2012, complete medical coverage and pharmacy benefits, no other primary malignancy, and no prior nab-P. Data were supplem...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
